Announced the successful seed fundraise of S$2.8 million fully subscribed by Genting Biocellular Sdn. Bhd., a wholly owned subsidiary of Malaysia based conglomerate Genting Berhad.
Completed validation trials for NovoTect™ Bc showing the upper range of test sensitivity is 83.3%, specificity 100% and positive predictive value 100%.
University of Oxford
Announced an exclusive collaboration and Asia licensing agreement for University of Oxford developed Epigenetic technology.